Herpes simplex virus thymidine kinase (HSV-TK) and
Introduction
Despite advances in the treatment of malignant gliomas, the prognosis for affected individuals remains poor. [1] [2] [3] [4] Over the past decade, novel treatment approaches utilizing virus-based gene therapeutic vectors have become a topic of intense study worldwide. A prominent strategy advanced to the stage of clinical trials involves the delivery of 'suicide genes' such as the herpes simplex virus thymidine kinase (HSVtk) or Escherichia coli cytosine deaminase (CD) genes whose products have the ability to convert largely harmless prodrugs into potent inhibitors of DNA synthesis. In the central nervous system (CNS), most cells are non-replicating and terminally differentiated, suggesting that gene therapy for CNS malignancies effecting cessation of DNA synthesis would be tumor cell-specific.
The HSVtk gene product phosphorylates the non-toxic prodrug ganciclovir, which results in the generation of a defective nucleoside analogue. Incorporation of this analogue into replicating DNA leads to termination of chain elongation and cell death by apoptosis. CD converts its substrate 5-fluorocytosine (5-FC) into the toxic anabolite 5-fluorouracil (5-FU), which is further processed by cellu- lar enzymes into either 5-fluorouracil triphosphate (5-FUTP) or 5-fluoro-2'-deoxyuridine 5'-monophosphate (5-FdUMP). 5-FUTP is incorporated into RNA and interferes with RNA processing, while 5-FdUMP irreversibly inhibits thymidylate synthase and hence DNA synthesis. 5 Both the HSVtk/GCV and CD/5-FC systems have been shown to kill unaltered neighboring tumor cells in addition to gene-modified (transduced) cells, a phenomenon referred to as the 'bystander effect'. 5, 6 For HSVtk/GCV, the bystander effect appears to depend on gap junctions which are believed to facilitate the migration of phosphorylated GCV from transduced to untransduced cells. 5-FU is freely diffusible across cell membranes allowing its spread from gene-modified to unmodified tumor cells. Both systems have been widely studied in vitro, in animal tumor models, and in clinical trials. [7] [8] [9] [10] [11] [12] [13] In this report, we have examined the possibility of mutual enhancement of the HSVtk/GCV and CD/5-FC systems in vitro and in rats with intracerebral 9L gliosarcoma implants. The vectors used in this study were replicationdefective derivatives of HSV-1 with deletions of the immediate early (IE) genes ICP4, ICP22 and ICP27. These triple IE gene deletion vectors have minimal cytotoxicity which permits largely unrestricted expression of therapeutic genes. While maintaining a high transduction efficiency, 14, 15 these vectors also offer an attractive safety profile in that they cannot spread from the site of initial infection and can be grown to high titers in comp-585 lementing cell lines without helper virus or the emergence of replication-competent revertants. Recombinant vectors were derived that expressed the CD and HSVtk genes separately or together and these vectors were tested in the presence of one or both prodrugs. The results demonstrated that double suicide gene therapy under our conditions was at best as effective as single therapy. Both single gene vectors with their matching prodrug were more effective in cell culture than the combination vector with the respective prodrugs, raising the suggestion that HSVtk and CD interact with each other's prodrug substrate or products.
Results

Recombinant viruses
We previously described an improved HSV-1-based vector, designated T.1, for HSVtk-dependent suicide gene therapy (Figure 1a) . 16 T.1 had both copies of the ICP4 gene deleted, which rendered the virus highly defective for early (E) and late (L) gene expression and incapable of productive infection. To assure synthesis of the HSVtk protein under these conditions, the native early promoter of the HSVtk gene (U L 23) was replaced by the ICP4 immediate-early (IE) promoter of HSV-1, a manipulation that also inactivated the U L 24 gene whose coding region partially overlaps the tk promoter. T.1 was in addition deleted for the essential ICP27 and non-essential ICP22 IE genes to reduce the undesirable cytotoxicity of HSV-1 vectors and promote extended transgene expression. 14 
Expression of the HSVtk and CD genes
The three vectors were compared for HSVtk expression by infection of Vero cells and immunoblotting. As shown in Figure 2a , the enzyme was observed in T.1-and TOCD/TK-infected cells but not in TOCD-infected cells, confirming that the HSVtk gene was expressed from the ICP4 IE promoter, but not from its own early promoter in the background of these triple IE-gene deleted vectors.
Separately, RNAs were extracted from infected Vero cells and analyzed by quantitative RT-PCR for HSVtk and CD gene expression using cellular ␤-actin RNA as 
Cytotoxicity in vitro
MTT cell viability assays were performed to assess the cytotoxic activities of different virus/prodrug combinations in cell culture. 17 Rat gliosarcoma 9L cells were infected at MOIs of 3.0 and 0.1 to achieve infection of a majority of the cells and to examine bystander cell killing, respectively. Separate cultures of TOCD/TK-infected cells were incubated with a range of concentrations of each prodrug alone or both prodrugs together, using ratios of 5-FC to GCV (weight/weight) of 25:1 (MOI = 3.0) or 10:1 (MOI = 0.1), as suggested in the literature. 7 For comparison, cultures infected with T.1 or TOCD were incubated with the same concentrations of GCV or 5-FC, respectively, and the cells were tested 3 days after infection.
At both MOIs, the selected prodrug concentrations yielded similar cell survival curves for T.1 with GCV and TOCD with 5-FC (Figure 3a and b) . Note that the prodrug units at the two MOIs were defined differently and that the maximum amounts of the two prodrugs tested at the lower MOI were actually higher than at the higher MOI. Although the shapes of the curves indicated that all the prodrug concentrations tested at both MOIs were limiting, the combination of the two suicide systems using the vector TOCD/TK together with both prodrugs showed no increased cytotoxicity at either MOI. This observation that two equally effective suicide systems administered together under limiting conditions failed to increase the cytotoxic effect over each system alone suggested negative interactions between the two systems. Since the same observation was made at high and low MOI, it appeared that these negative interactions impaired the production rather than spread of the predicted toxic prodrug derivatives.
To determine whether the lack of additive effect between the two suicide systems was due to inactivity of one of the two or to mutual interference, we compared the cytotoxicities of the combination vector in the presence of one, the other, or both prodrugs. The results indicated that both systems were active when combined, since the combination vector was generally most effective in the presence of both prodrugs, although not substantially at the higher MOI compared with 5-FC alone (Figure 3c and d) . The suggestion from these results that each system was inhibited by co-expression of the other system's enzyme was confirmed by the direct comparisons of single and double enzyme vectors in the presence of a single prodrug shown in the remaining panels of Figure 3 (e-h). GCV was more cytotoxic with the TK vector T.1 than with the combination vector (e, f) and likewise, 5-FC was generally more effective with TOCD than with TOCD/TK (g, h). These results represented direct evidence that HSVtk and CD can act as mutual antagonists when expressed in the same cells.
Cytotoxicity in vivo
Although appropriate as a model, cell killing in vitro excludes certain effects that may influence the outcome of suicide gene therapy in vivo, including effects of the immune system, the nature of the tumor, and the tumor's environment. We therefore tested the potential of combination suicide therapy in vivo. Brain tumors were established in Fisher 344 rats by intracerebral implantation of 10 5 9L cells and treatment was started 5 days later by vector injection at the same coordinates (2 × 10 7 p.f.u.) and daily intraperitoneal administration of prodrug(s) or medium for 1 week. Animals were killed at the onset of neurological symptoms or other signs of serious disease. The survival plot of Figure 4a demonstrates that treatment with the combination vector TOCD/TK alone or Gene Therapy together with the two prodrugs GCV and 5-FC failed to prolong the survival of tumor-bearing rats compared with mock treatment (median survival 28-29 days), whereas the mono-enzymatic HSVtk vector T.1 combined with GCV treatment provided a modest survival benefit (median 38 days). In a separate experiment, the monoenzymatic CD vector TOCD in combination with 5-FC was found to approximate the effectiveness of the T.1/GCV combination (Figure 4b ). While none of the three vectors alone produced a treatment effect, T.1-and TOCD-injected animals showed a beneficial response to Gene Therapy
Figure 4 Kaplan-Meier survival plots of Fisher 344 rats with intracerebral implants of 1 × 10 5 9L tumor cells. Tumor treatment was started with a single viral injection of TOCD/TK, TOCD or T.1 5 days after cell implantation and completed by intraperitoneal administration of GCV (30 mg/kg) and/or 5-FC (300 mg/ml) on 7 consecutive days. Median survival times and the number of animals per treatment (n) are shown in the key.
prodrug administration, while TOCD/TK did not. These results suggested that single-vector dual suicide gene therapy may offer no advantages over conventional single suicide gene therapies for the treatment of cancer.
Discussion
The biggest challenge in the emerging field of cancer gene therapy is the delivery of adequate numbers of therapeutic mediators to each and every malignant cell in the host. Current gene delivery systems remain highly deficient in their ability to transduce a majority of targeted tumor cells in vivo. While mechanisms such as the in situ activation of diffusible cytotoxic drugs by transduced cells can expand the reach of tumoricidal gene therapies, these mechanisms alone are completely effective only in very rare instances. For high-mortality solid tumors such as malignant glioma, suicide gene therapy with an associated bystander effect may hold promise in controlling recurrence at the periphery following treatment by surgery and other conventional procedures, but the beneficial effects in this setting as well leave room for improvement. Others have reported increased anti-tumor cell efficacy by combinations of the HSVtk and E. coli CD systems, leading us to examine this combination in a model study using vectors based on the neurotropic virus HSV-1.
We constructed and tested a set of triple IE genedeleted, replication-defective HSV-1 vectors for intracellular delivery and expression of the two suicide genes, separately or together. As reported previously, these debilitated vectors can safely transduce various regions of the brain with minimal cytotoxicity. 15, [18] [19] [20] [21] Vector cytotoxicity is undesirable in suicide gene therapy because it limits the killing of uninfected cells by the bystander effects of the HSVtk/GCV and CD/5-FC systems. Despite their defects, these vectors remain highly infectious, reaching a transduction efficiency of nearly 100% in vitro at an MOI of 3. Transcription of the two suicide genes was controlled by promoters of the immediate-early type to accommodate the ICP4 deficiency of the vectors, which prevents activation of early and late HSV promoters, including the native tk promoter. We used these vectors to examine the efficiency of cell killing by the single and combined suicide systems in vitro under conditions that are presently elusive in vivo -a transduction rate approaching 100% -and under conditions that more realistically represent the average success of vector delivery in vivo -a Ͻ5% transduction rate. At the higher transduction rate, the sensitivity of enzyme-expressing cells to one, the other, or both prodrugs could be compared, while the efficiency of bystander killing was at issue at the lower transduction rate. Subsequently, in vivo experiments measuring animal survival were performed in which the vectors were injected into established brain tumors and the prodrugs administered at a peripheral site.
The results both in vitro and in vivo indicated that combining the two suicide systems offered no improvement over each system alone. Although the combination vector in the presence of both GCV and 5-FC was somewhat more effective than when either prodrug was omitted, suggesting that both suicide systems were active, the two single-gene vectors in the presence of their corresponding prodrugs were as effective against 9L cells in culture and more effective in vivo. In cell culture, the combination vector was generally inferior to the single-gene vectors when tested in the presence of a single prodrug, indicating a negative interaction between each system and the gene or enzyme of the other system. By quantitative RT-PCR, we found no evidence that one or both of the suicide genes was underexpressed from the combination vector compared with the single-gene vectors, arguing that the reciprocal interference occurred at a post-transcriptional stage. The results of experiments at high and low MOI in culture were very similar, suggesting that interference occurred in the population of infected cells, rather than in the killing of uninfected cells, the targets of the bystander effect. Together, these results raised the possibility that TK and CD act on each other's prodrug substrate or metabolites. For example, 5-FdUMP derived from 5-FU, the CD conversion product of 5-FC, is a strong inhibitor of thymidine synthase. TK-mediated phosphorylation of 5-FdUMP would produce the less toxic substances 5-FdUDP and 5-FdUTP, thereby reducing the cytotoxicity of the CD/5-FC system. Conversely, it is possible that CD-mediated deamination of TK-activated GCV or its toxic derivative diminishes the cytotoxicity of the TK/GCV system. However, we have as yet no experimental evidence in support of these direct mechanisms and it is possible that complex feedback loops influencing enzyme activities and drug accumulation play a central role.
589
Our observations differ from those of Aghi and coworkers who used the Loewe and the Chou-Talalay isobologram methods to analyze the drug responses of stably transfected 9L cell clones expressing HSVtk, CD, or both from separate plasmids. 7 These authors demonstrated synergy between the TK/GCV and CD/5-FC systems in homogeneous cell cultures, mixed cultures revealing the bystander effect, and ex vivo. As both studies used the same concentrations and ratios of GCV and 5-FC, the difference in the results may be related to the cells. Both studies used 9L cells, but the cell lines used by Aghi and co-workers were clonal derivatives generated by transfection (or infection to create the CD line) followed by selection, whereas our cells were populations of infected, unselected cells. The report by Aghi et al did not provide information on the expression levels of the two suicide genes in the three clones used in their study, but their comparisons of survival in the presence of either single prodrug indicate equal expression in singly and doubly transduced lines. At the same prodrug concentrations, survival was lower in their studies than in ours, suggesting higher expression levels of both enzymes in their clonal cultures, if not in each individual cell. Since our viral vectors were replication defective, gene amplification following infection could not occur in our experiments, whereas transfected cell lines often maintain multiple copies of the foreign gene(s). Expression following viral infection also follows different kinetics than expression in established cell lines, another expression variable that could influence the results. Finally, cell-tocell variations in the relative and absolute expression of the two enzymes may occur in both systems, but neither system was examined in this respect. Although transfected cell lines are a less realistic model for gene therapy applications than viral infection, the discrepancy in the results between these two studies remains to be adequately explained.
Using widely different systems, other groups have also reported enhanced cytotoxicity for the combination of TK/GCV and CD/5-FC although the radiosensitizing effects of the combination were more dramatic in some of these studies than the direct cytotoxic effects.
9,11 Explanations for the different conclusions from these studies compared with ours may be found among the many variables between the experimental systems, but until the decisive variables have been identified, our study should serve as a cautionary note against the emerging dogma that the combination of HSV-TK/GCV and CD/5-FC therapies is the preferable system for clinical studies compared with either single therapy.
Materials and methods
Cell culture and virus preparations
Vero African green monkey kidney cells (CCL81; ATCC, Rockville, MD, USA) and Vero-derived 7b cells 15 were maintained in MEM (Life Technologies, Gaithersburg, MD, USA) supplemented with glutamine, antibiotics (PSN; Life Technologies), and 10% heat-inactivated fetal bovine serum (Life Technologies). 9L rat gliosarcoma cells (kindly provided by Dr KM Culver, NIH) were maintained in DMEM supplemented with glutamine and 10% fetal bovine serum (FBS).
HSV-1 stocks were prepared by infecting 7B cells, Gene Therapy which supply the ICP4 and ICP27 proteins in trans, 15 at a multiplicity of 0.03. Infected cells were harvested when a 100% cytopathic effect was evident and subjected to three cycles of freeze-thawing (Ϫ80°C/37°C) and a single burst of sonication. The virus was then separated from cell debris by centrifugation and purified on a continuous Nycodenz (Life Technologies) gradient. Virus stocks were aliquoted into 2-ml cryogenic tubes (Corning Glass Works, Corning, NY, USA) and stored at Ϫ80°C. Final titers averaged 2 × 10 8 to 2 × 10 9 p.f.u./ml
Construction of recombinant HSV-1 vectors
The HSVtk expression vector T.1 has been described previously. 16, 20 The CD gene (pCD2) was obtained from ATCC. Plasmid p41-LZ contained HSV-1 U L 41 sequences straddling a LacZ expression cassette using the HSV-1 ICP0 promoter (ICP0p). The CD gene was placed between the EcoRI and BamHI sites of p41-LZ replacing the LacZ gene. The resulting p41-CD plasmid was recombined with the U L 41 locus of the previously described viral construct TOZ.1 16, 20 to obtain the combination vector TOCD/TK which was identical to T.1, except for the ICP0p-CD cassette in U L 41.
The strategy to generate CD expression vector TOCD was to silence the HSVtk gene of vector TOCD/TK by replacement of the ICP4 IE promoter controlling the tk gene in TOCD/TK with the native tk promoter, which functions as an early promoter and is inactive in the IE gene-deficient environment of our vectors. Plasmid pUX used for this purpose contained the complete promoter and coding sequences of the HSVtk gene (BamHI fragment I). Virus recombinants produced by homologous recombination were obtained by three rounds of selection in media containing 100 g/ml Ara-T (thymine 1-␤-Darabinofuranoside, Sigma, St Louis, MO, USA). Both TOCD/TK and TOCD were purified by three rounds of limiting dilution and their genome structures verified by Southern blot hybridization.
Southern blot analysis of virus constructs
BamHI-or PstI-digested viral DNAs were electophoresed on 1% agarose gels in TAE buffer, blotted to Nytran membrane (Schleicher and Schuell, Keene, NH, USA), and crosslinked in a UV Stratalinker 2400 (Stratagene, La Jolla, CA, USA). The membranes were probed with chemiluminescent-labeled probes specific for the cytosine deaminase gene (a 1. Immunoblotting for TK expression Mock-and virus-infected Vero cells (MOI = 3) were lysed 36 h after infection and extracted proteins analyzed by Western blot as described previously, 19 using a 1:5000-diluted HSVtk-specific antibody. 22 
RNA isolation and quantitative RT-PCR
Total cellular RNA was extracted from 2 × 10 6 virusinfected Vero cells (MOI = 3) with the use of Isogen (Nippon Gene, Japan) according to the manufacturer's
